Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 252263 (IRAS) | Other Identifier | Health Research Authority | |
| 19/LO/0404 (REC) | Other Identifier | Health Research Authority |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cancer Research UK | OTHER |
| University of Manchester | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The Manchester Lung Health Study (qUEST) will assess the uptake of a community-based lung cancer screening service and its impact across a deprived area of North and East Manchester, which has high rates of lung cancer. One measure will be to compare the number and stage of lung cancers detected through screening to those detected outside of screening. In addition we will investigate the potential of a blood and nose test to detect lung cancer or to help decide who would benefit from screening. We will also see if these samples can help with the interpretation of CT scans. One of the problems with lung cancer CT screening is that you detect lung nodules in which we are not sure if they are benign or cancerous. Therefore we are also looking to see if a biomarker can help us work out which are cancerous and which are benign.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Data (main study) | This study group is for any individual that attends and has a lung health check. The data collected for this study group is to evaluate the uptake and performance of a community-based lung health check / lung screening programme. |
| |
| Biomarker (sub-study) | This sub-study is for participants that are determined to require a CT scan through their lung health check and have also signed up to the data part of the study. This part of the study is to evaluate the potential for biomarkers to improve the early detection of lung cancer. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lung Cancer Screening | Diagnostic Test | The lung health check consists of a symptom questionnaire for the calculation of 6-year lung cancer risk (using the PLCOM2012 model) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Uptake of the Manchester lung health check service | The overall uptake will be assessed and analysed according to age, sex, smoking status, ethnicity and socio economic status. | Over 3 years to determine long term outcomes from screening |
| Evaluation of biomarkers | Sensitivity and specificity of a biomarker or panel of biomarkers to detect early stage lung cancer. | Over 3 years to determine long term outcomes from screening |
| Measure | Description | Time Frame |
|---|---|---|
| Screening adherence | overall and according to patient characteristics (age, sex, smoking status, ethnicity and socio economic status). | Over 3 years to determine long term outcomes from screening |
| Evaluation of screening numbers required to detect lung cancer |
Not provided
Main data study:
Inclusion Criteria:
- Any individual attending the Manchester Lung Health service who has a lung health check as they meet the service inclusion exclusion criteria (see below):
Manchester Lung Health service inclusion criteria:
Manchester Lung Health service exclusion Criteria:
Exclusion Criteria:
- Unable to give informed consent to study participation.
Biomarker sub-study:
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Individuals will be attending a lung health check as they are registered to a GP practice in north and east Manchester, between the ages of 55-80 and an ever smoker.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Philip Crosbie | Contact | 01612912116 | philip.crosbie@manchester.ac.uk | |
| Sara Waplington | Contact | 01612912835 | sara.waplington@mft.nhs.uk |
| Name | Affiliation | Role |
|---|---|---|
| Philip Crosbie | Manchester University NHS Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Manchester University NHS Trust | Recruiting | Manchester | United Kingdom |
Only fully anonymised data will be sent to collaborating researchers
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000074062 | Environmental Biomarkers |
| ID | Term |
|---|---|
| D015415 | Biomarkers |
| D001685 | Biological Factors |
| D001686 | Biological Phenomena |
| D004784 | Environmental Monitoring |
Not provided
Not provided
Not provided
Not provided
Not provided
A blood sample of up to 50mL will be taken from participants for analysis of circulating tumour cells, circulating nucleic acid, proteins and genetic variations (single nucleotide polymorphisms).
Nasal swab and brush samples will be taken for the identification of inflammatory markers.
| Biomarkers | Diagnostic Test | This will explore the role of biomarkers for the early detection of lung cancer. These include circulating nucleic acids, circulating proteins, circulating tumour cells and inflammatory markers. |
|
Number needed to screen to detect one lung cancer according to lung cancer risk (as calculated by PLCOM2012). |
| Over 3 years to determine long term outcomes from screening |
| Comparison between cohort and those residents diagnosed in north and east manchester | Lung cancer stage in the screened cohort compared to lung cancers diagnosed in residents of N+EM outside of the screening service. | Over 3 years to determine long term outcomes from screening |
| Histological subtype for lung cancer related to screening service | Histological subtype of lung cancers in screening and outside of screening during the course of the service. | Over 3 years to determine long term outcomes from screening |
| Treatment for lung cancer related to screening service | Treatment of lung cancers in screening and outside of screening during the course of the service. | Over 3 years to determine long term outcomes from screening |
| Diagnosis route for lung cancer related to screening service | Route to diagnosis of lung cancers in screening and outside of screening during the course of the service. | Over 3 years to determine long term outcomes from screening |
| False positive rates | False positive rates in those undergoing LDCT screening. | Over 3 years to determine long term outcomes from screening |
| False negative rates | False negative rates in those undergoing LDCT screening. | Over 3 years to determine long term outcomes from screening |
| Rates of investigation of benign disease | Rates of investigation of benign disease in those undergoing LDCT screening. | Over 3 years to determine long term outcomes from screening |
| Benign resection rate in participants | Benign resection rate in participants for those that have undergoing LDCT screening. | Over 3 years to determine long term outcomes from screening |
| Interval cancers | Interval cancers in those undergoing LDCT screening. | Over 3 years to determine long term outcomes from screening |
| Recall rates | Recall rates in those undergoing LDCT screening. | Over 3 years to determine long term outcomes from screening |
| Resection rates generated from screening | Resection rates generated from screening including incidental findings. | Over 3 years to determine long term outcomes from screening |
| Investigations generated from screening | Investigations generated from screening including incidental findings. | Over 3 years to determine long term outcomes from screening |
| Adverse events generated from screening | Adverse events generated from screening including incidental findings. | Over 3 years to determine long term outcomes from screening |
| Assessment of the British Thoracic Society pulmonary nodule guidelines | Assessment of performance of the BTS pulmonary nodules guideline in the setting of screening service. | Over 3 years to determine long term outcomes from screening |
| Smoking prevalence | Smoking prevalence and amount at the start and end of screening. | Over 3 years to determine long term outcomes from screening |
| Undiagnosed airflow obstruction | Prevalence of undiagnosed airflow obstruction in the screened population. | Over 3 years to determine long term outcomes from screening |
| Coronary artery calcification | Prevalence of coronary artery calcification and QRISK2 score. | Over 3 years to determine long term outcomes from screening |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D004781 |
| Environmental Exposure |
| D004787 | Environmental Pollution |
| D011634 | Public Health |
| D004778 | Environment and Public Health |